Literature DB >> 19368137

Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study.

Giammaria Fiorentini1, Camillo Aliberti, Alessandro Del Conte, Massimo Tilli, Susanna Rossi, Pierluigi Ballardini, Gina Turrisi, Giorgio Benea.   

Abstract

BACKGROUND: Uveal melanoma (UM) is the most common primary intraocular malignancy in adults and the liver is the predominant site of metastases (LM). If metastases appear, none of the systemic treatments established for cutaneous melanoma so far have any significant impact. Several authors have adopted transarterial chemoembolization (TACE) as palliation. TACE combines hepatic artery embolization with infusion of concentrated doses of chemotherapeutic drugs. DC Beads are new embolic products that can be loaded with irinotecan (IRI). The beads consist of polyvinyl alcohol microspheres modified with sulfonic acid groups and are available at different size ranges from 100 to 900 microns in diameter. The use of IRI as drug-eluting beads seems to optimize TACE in UM.
OBJECTIVE: Our purpose was to assess the safety and efficacy of this new kind of TACE in a phase II clinical study. PATIENTS AND METHODS: Ten patients with LM from UM were treated with TACE-containing beads preloaded with IRI (100 mg).
RESULTS: All patients had an objective response, three presented a very good partial response and seven obtained a partial response. The median follow-up time from the beginning of therapy was 6.5 months (range 4-9 months). Eight patients are alive at the time of this analysis. The most important adverse event was abdominal pain during the procedure. Adequate supportive treatment with antibiotic and antiemetic prophylaxis, desametazone and intravenous hydration is strictly necessary until stabilization of serum levels of transaminases and to prevent infections. A major analgesic such as morphine must be used before and after the procedure.
CONCLUSION: TACE containing beads preloaded with IRI is effective in the treatment of LM from UM. This approach seems to have better efficacy than previous TACE regimens adopted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19368137

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  15 in total

1.  Quantification of irinotecan, SN38, and SN38G in human and porcine plasma by ultra high-performance liquid chromatography-tandem mass spectrometry and its application to hepatic chemoembolization.

Authors:  Xiaohong Chen; Cody J Peer; Raul Alfaro; Tian Tian; Shawn D Spencer; William D Figg
Journal:  J Pharm Biomed Anal       Date:  2012-01-16       Impact factor: 3.935

Review 2.  Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy.

Authors:  Andrew L Lewis; Matthew R Dreher
Journal:  J Control Release       Date:  2012-01-21       Impact factor: 9.776

Review 3.  Rationale of transcatheter intra-arterial therapies of hepatic cancers.

Authors:  Ryan M Hickey; Robert J Lewandowski; Riad Salem
Journal:  Hepat Oncol       Date:  2014-09-09

Review 4.  Locoregional Therapies for the Treatment of Uveal Melanoma Hepatic Metastases.

Authors:  Carin F Gonsalves; Robert D Adamo; David J Eschelman
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

5.  Synthesis and characterization of image-able polyvinyl alcohol microspheres for image-guided chemoembolization.

Authors:  Ayele H Negussie; Matthew R Dreher; Carmen Gacchina Johnson; Yiqing Tang; Andrew L Lewis; Gert Storm; Karun V Sharma; Bradford J Wood
Journal:  J Mater Sci Mater Med       Date:  2015-06-24       Impact factor: 3.896

6.  Hepatic artery infusion of melphalan in patients with liver metastases from ocular melanoma.

Authors:  Brian A Boone; Samantha Perkins; Rupal Bandi; Ernesto Santos; Kevin McCluskey; David L Bartlett; James F Pingpank
Journal:  J Surg Oncol       Date:  2018-04       Impact factor: 3.454

7.  Management of uveal melanoma: a consensus-based provincial clinical practice guideline.

Authors:  E Weis; T G Salopek; J G McKinnon; M P Larocque; C Temple-Oberle; T Cheng; J McWhae; R Sloboda; M Shea-Budgell
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

8.  Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases.

Authors:  Matias E Valsecchi; Mizue Terai; David J Eschelman; Carin F Gonsalves; Inna Chervoneva; Jerry A Shields; Carol L Shields; Akira Yamamoto; Kevin L Sullivan; MaryAnn Laudadio; David Berd; Michael J Mastrangelo; Takami Sato
Journal:  J Vasc Interv Radiol       Date:  2015-02-09       Impact factor: 3.464

Review 9.  Transhepatic therapies for metastatic uveal melanoma.

Authors:  David J Eschelman; Carin F Gonsalves; Takami Sato
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

Review 10.  Isolated hepatic perfusion for patients with liver metastases.

Authors:  Srinevas K Reddy; Susan B Kesmodel; H Richard Alexander
Journal:  Ther Adv Med Oncol       Date:  2014-07       Impact factor: 8.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.